\-\ Texto\\:\\ \ \(0\)\
\-\ urinalysis\\ demonstrated\\ 4\\+\\ blood\\.\ \(0\)\
\-\ large\\ heterogeneous\\ enhancing\\ mass\\ arising\\ from\\ the\\ right\\ kidney\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\ \(60\)\
\-\ this\\ large\\ enhancing\\ heterogeneous\\ mass\\ is\\ virtually\\ pathognomonic\\ for\\ renal\\ cell\\ carcinoma\\.\\ \\ renal\\ lymphoma\\ is\\ frequently\\ infiltrative\\ and\\ if\\ solid\\,\\ usually\\ hypoenhancing\\ when\\ compared\\ to\\ the\\ normal\\ renal\\ parenchyma\\.\\ \\ renal\\ metastases\\ are\\ usually\\ small\\ and\\ multifocal\\.\\ \\ oncocytomas\\ are\\ relatively\\ uncommon\\,\\ large\\,\\ homogeneous\\ masses\\ frequently\\ with\\ a\\ central\\ fibrous\\ scar\\ in\\ asymptomatic\\ patients\\.\ \(0\)\
\-\ 66\\ yo\\ female\\ with\\ painless\\ hematuria\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.44390503296128353\ \(0\)\
\-\ frequently\\:\\ 0\\.23481565730334134\ \(0\)\
\-\ large\\:\\ 0\\.21430065606468107\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.20637481544963718\ \(0\)\
\-\ hypoenhancing\\:\\ 0\\.2050963350294628\ \(0\)\
\-\ oncocytomas\\:\\ 0\\.2050963350294628\ \(0\)\
\-\ usually\\:\\ 0\\.17950344268916085\ \(0\)\
\-\ enhancing\\:\\ 0\\.17862045655801603\ \(0\)\
\-\ carcinoma\\:\\ 0\\.17055524530008828\ \(0\)\
\-\ cell\\:\\ 0\\.16311071648607775\ \(0\)\
\-\ virtually\\:\\ 0\\.1594958068368223\ \(0\)\
\-\ urinalysis\\:\\ 0\\.15440730638417977\ \(0\)\
\-\ infiltrative\\:\\ 0\\.14609207030188723\ \(0\)\
\-\ pathognomonic\\:\\ 0\\.1402337489939639\ \(0\)\
\-\ multifocal\\:\\ 0\\.13843493236945528\ \(0\)\
\-\ scar\\:\\ 0\\.1345822809491828\ \(0\)\
\-\ 66\\:\\ 0\\.13370525190680932\ \(0\)\
\-\ painless\\:\\ 0\\.1320384501841691\ \(0\)\
\-\ uncommon\\:\\ 0\\.12900530703730184\ \(0\)\
\-\ hematuria\\:\\ 0\\.12608804490328163\ \(0\)\
\-\ homogeneous\\:\\ 0\\.1258771342585124\ \(0\)\
\-\ relatively\\:\\ 0\\.11609595395313997\ \(0\)\
\-\ parenchyma\\:\\ 0\\.11581354684571561\ \(0\)\
\-\ compared\\:\\ 0\\.11525812925305584\ \(0\)\
\-\ metastases\\:\\ 0\\.11525812925305584\ \(0\)\
\-\ arising\\:\\ 0\\.1132787763538063\ \(0\)\
\-\ fibrous\\:\\ 0\\.11074722603933106\ \(0\)\
\-\ solid\\:\\ 0\\.1092995790273074\ \(0\)\
\-\ mass\\:\\ 0\\.1089141983832044\ \(0\)\
\-\ are\\:\\ 0\\.10819600318077138\ \(0\)\
\-\ kidney\\:\\ 0\\.10015910626008287\ \(0\)\
\-\ masses\\:\\ 0\\.09705743694410025\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.09705743694410025\ \(0\)\
\-\ central\\:\\ 0\\.09520527395337264\ \(0\)\
\-\ yo\\:\\ 0\\.08906828289405008\ \(0\)\
\-\ demonstrated\\:\\ 0\\.08761834286279598\ \(0\)\
\-\ when\\:\\ 0\\.0861192093375042\ \(0\)\
\-\ lymphoma\\:\\ 0\\.08490796123932695\ \(0\)\
\-\ if\\:\\ 0\\.08283544299350076\ \(0\)\
\-\ blood\\:\\ 0\\.08279794446720937\ \(0\)\
\-\ patients\\:\\ 0\\.08020219258717991\ \(0\)\
\-\ is\\:\\ 0\\.07808632911883509\ \(0\)\
\-\ small\\:\\ 0\\.07354128012351177\ \(0\)\
\-\ female\\:\\ 0\\.06879554607092209\ \(0\)\
\-\ and\\:\\ 0\\.058919786757484834\ \(0\)\
\-\ normal\\:\\ 0\\.05820948263222833\ \(0\)\
\-\ the\\:\\ 0\\.056894889710560004\ \(0\)\
\-\ from\\:\\ 0\\.05662189160206075\ \(0\)\
\-\ with\\:\\ 0\\.055833120811656874\ \(0\)\
\-\ this\\:\\ 0\\.048988868437863584\ \(0\)\
\-\ right\\:\\ 0\\.047267129311091206\ \(0\)\
\-\ for\\:\\ 0\\.04321121035932578\ \(0\)\
\-\ to\\:\\ 0\\.035641673534997816\ \(0\)\
\-\ in\\:\\ 0\\.035466245291675\ \(0\)\
